Categories
Connect with us on LinkedIn
Castor adds nearly 10 commercial Phase II/III eCOA studies in H2 2025
Nearly 10 Phase II/III eCOA studies and 12 validated instruments across four therapeutic areas. Castor’s H2 2025 platform...
Data management without the coordination friction
Castor replaces disconnected DM tools and CRO handoffs with one platform and one expert team. Fixed-fee, submission-ready.
Biotech clinical trial data management
Castor delivers expert data management for biotech trials. Submission-ready from day one. No intermediary layers.
ICH E6(R3) compliance for biotech studies
See how Castor's unified platform helps biotech sponsors meet ICH E6(R3) oversight, data integrity, and site burden requirements.
ePRO for biotech: capture economic evidence from day one
Castor ePRO helps biotech sponsors capture HEOR-ready evidence from Phase I/II. Audit-proof, 92%+ participant compliance.
Joel White’s Q4 CRO breakdown: strong bookings, a sell-off that didn’t match, and the disruption gap nobody is talking about
Joel White and Derk Arts break down Q4 2025 CRO results: biotech rebound data, AI fears, and what...
Phase 4 and real-world evidence: not a spectrum, a strategic choice
Phase 4 is a post-approval interventional trial that fulfills regulatory commitments. Real-world evidence spans PASS, PAES, HEOR, natural...
Castor Joins C-Path eCOA Consortium, Surpassing 300 Industry Study Milestone
Castor joins the Critical Path Institute (C-Path) eCOA Consortium, bringing insights from 300+ industry studies to advance participant-centric...
Obesity RWD Compliance: The Direct-to-Patient Guide
Over 2,000 active obesity and GLP-1 studies are competing for the same patients. Most still run on traditional...
Own Your Data, Accelerate Your Cure Castor Catalyst — Rare Disease Insight Brief
Rare disease foundations no longer need to wait for pharmaceutical industry interest to develop treatments for their communities....
Castor’s Global e-Consent Matrix
Electronic consent is now approved or conditionally approved in 27 of 33 countries assessed in Castor's eConsent Country...
ICH E6(R3) is here: what your centralized monitoring strategy needs right now
ICH E6(R3) is in effect. Castor's recap covers centralized monitoring, sponsor accountability, and closing the biotech RBQM gap.
Practical ICH E6(R3) Oversight for Your Centralized Monitoring Strategy – On Demand
Adopting ICH E6(R3) requires a shift from site-based monitoring to centralized oversight. Watch this on-demand Product Spotlight to...
Castor Professional Services: Expert Clinical Study Builds
Castor’s Professional Services team offers end-to-end support for clinical trial implementation, including EDC build, eCOA, and data management....
The real-time monitoring dilemma
Offline eCOA capability creates regulatory tension with EMA device-as-source requirements while eliminating real-time monitoring capabilities that drive 80-95%...
SCOPE 2026 Meet us at Booth #1612
February 2nd – 5th | Rosen Shingle Creek in Orlando, Florida
Join Castor at SCOPE US 2026, February 2-5 at Orlando's Rosen Shingle Creek. Discover how our "self-driving" clinical...
Executing Concurrent Decentralized RCTs and RWE at Scale
Discover how Sword Health used Castor to validate digital MSK care with scalable RCTs and real-world evidence strategies.
3-Week Database Builds That Withstood FDA Review
Castor’s EDC enabled Gameto’s 3-person team launch in 3 weeks, run 9 IVF studies on 4 continents, and...